1-2 of 2
Linda Garrett, RN
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Disease (MRD) As Exploratory Endpoint in a Phase 1 Study of the Anti-CD123 Mab CSL362 Given As Post-Remission Therapy in Adult Acute Myeloid Leukemia (AML)

B. Douglas Smith, MD, Andrew W. Roberts, MBBS, PhD, Gail J. Roboz, MD, Mark DeWitte, VMD, Anna Ferguson, BSN, RN, Linda Garrett, RN, Tania Curcio, Kaysey F. Orlowski, Sue Dasen, MS, Debra M. Bensen-Kennedy, MD, Roland B. Walter, MD PhD MS
Journal: Blood
Blood (2015) 126 (23): 3819.
https://doi.org/10.1182/blood.V126.23.3819.3819
Published: 2015
Journal Articles

First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse

B. Douglas Smith, MD, Gail J. Roboz, MD, Roland B. Walter, MD PhD, Jessica K. Altman, MD, Anna Ferguson, BSN, RN, Tania J. Curcio, R.N, Kaysey F. Orlowski, Linda Garrett, RN, Samantha J Busfield, PhD, Megan Barnden, PhD, Brad Sedgmen, PhD, Souravi Ghosh, PhD, Sarah Hosback, PhD, Roslyn Davis, MSc, Allison Dyson, BSc, Sue Dasen, MS, Mark DeWitte, VMD, Debra M. Bensen-Kennedy, MD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2014) 124 (21): 120.
https://doi.org/10.1182/blood.V124.21.120.120
Published: 2014